Back to results
US 5,840,731 AGranted
Pain-alleviating drug composition and method for alleviating pain
AssigneeVirginia Commonwealth University
InventorsDavid J. Mayer, Donald D. Price, Jianren Mao, John W. Lyle
Life of this patent
Estimating the term…
Abstract
The analgesic effectiveness of a combination drug composition containing at least one analgesic is significantly enhanced by the addition of a nontoxic N-methyl-D-aspartate (NMDA) receptor antagonist thereto.
Claims3
A drug composition comprising:
- a) a pharmacologically effective amount of an opioid analgesic selected from the group consisting of morphine, heroin, hydromorphone, oxymorphone, levorpbanol, levallorphan, codeine, hydrocodone, oxycodone, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine, their mixtures and their pharmaceutically acceptable salts;
- b) a pharmacologically effective amount of a second component which is the nonopioid analgesic acetaminophen;
- and,
- c) an analgesia-enhancing amount of a third component which is a nontoxic N-methyl-D-aspartate receptor antagonist selected from the group consisting of dextrorphan, dextromethorphan, their mixtures and their pharmaceutically acceptable salts.
1 more element
A method for alleviating pain which comprises administering to a mammal which is either experiencing pain or is about to be subjected to a pain-causing event a pain-alleviating amount of a drug composition comprising:
- a) a pharmacologically effective amount of a first component which is an opioid analgesic selected from the group consisting of morphine, heroin, hydromorphone, oxymorphone, levorphanol levallorphan, codeine, hydrocodone, oxycodone, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine, their mixtures and their pharmaceutically acceptable salts;
- b) a pharmacologically effective amount of a second component which is the nonopioid analgesic acetaminophen;
- and,
- c) an analgesia-enhancing amount of a third component which is a nontoxic N-methyl-D-aspartate receptor antagonis selected from the group consisting of dextrorphan, dextromethorphan, their mixtures and their pharmaceutically acceptable salts.
1 more element
Dependencies are inferred from the claim text.